Apellis Pharmaceuticals (APLS) Competitors $35.04 -0.38 (-1.07%) (As of 12:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends APLS vs. MRNA, VTRS, GMAB, SMMT, SRPT, RDY, PCVX, CTLT, QGEN, and ROIVShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Catalent (CTLT), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Moderna Viatris Genmab A/S Summit Therapeutics Sarepta Therapeutics Dr. Reddy's Laboratories Vaxcyte Catalent Qiagen Roivant Sciences Moderna (NASDAQ:MRNA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do analysts rate MRNA or APLS? Moderna presently has a consensus price target of $83.33, suggesting a potential upside of 91.39%. Apellis Pharmaceuticals has a consensus price target of $49.94, suggesting a potential upside of 41.01%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 3 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.19Apellis Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.75 Which has higher earnings & valuation, MRNA or APLS? Apellis Pharmaceuticals has lower revenue, but higher earnings than Moderna. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$6.85B2.45-$4.71B-$5.82-7.48Apellis Pharmaceuticals$396.59M11.11-$528.63M-$2.03-17.45 Which has more volatility & risk, MRNA or APLS? Moderna has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Does the media refer more to MRNA or APLS? In the previous week, Moderna had 7 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 21 mentions for Moderna and 14 mentions for Apellis Pharmaceuticals. Moderna's average media sentiment score of 0.76 beat Apellis Pharmaceuticals' score of 0.42 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in MRNA or APLS? 75.3% of Moderna shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 15.2% of Moderna shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is MRNA or APLS more profitable? Apellis Pharmaceuticals has a net margin of -34.97% compared to Moderna's net margin of -43.77%. Moderna's return on equity of -17.68% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Moderna-43.77% -17.68% -13.35% Apellis Pharmaceuticals -34.97%-103.11%-28.96% Does the MarketBeat Community favor MRNA or APLS? Apellis Pharmaceuticals received 131 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.52% of users gave Apellis Pharmaceuticals an outperform vote while only 55.50% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21255.50% Underperform Votes17044.50% Apellis PharmaceuticalsOutperform Votes34367.52% Underperform Votes16532.48% SummaryApellis Pharmaceuticals beats Moderna on 10 of the 19 factors compared between the two stocks. Ad Darwin"Start Earning Extra Income with Just $30"What if you could unlock a steady income stream from stocks priced under $30? Our new guide walks you through simple, effective options strategies designed for everyday investors. With step-by-step insights, you’ll learn how to transform familiar names like Ford and Intel into reliable monthly income generators.Claim Your Free Report Now: “Options Made Simple – 2 Affordable Stocks for Monthly Income” Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.41B$7.05B$5.37B$8.94BDividend YieldN/A7.97%5.33%4.05%P/E Ratio-17.4511.31117.7718.01Price / Sales11.11242.101,425.09155.72Price / CashN/A62.0542.8638.60Price / Book18.5410.647.356.66Net Income-$528.63M$152.36M$118.53M$224.93M7 Day Performance8.55%3.48%3.40%2.50%1 Month Performance26.59%-1.31%2.50%10.23%1 Year Performance-42.48%31.73%36.24%30.14% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.5294 of 5 stars$35.04-1.1%$49.94+42.5%-42.5%$4.36B$396.59M-17.26702Short Interest ↑MRNAModerna4.5795 of 5 stars$43.06-0.8%$83.33+93.5%-44.6%$16.57B$6.85B-7.405,600VTRSViatris2.3792 of 5 stars$13.15+0.5%$13.33+1.4%+40.9%$15.70B$15.05B-17.6938,000Short Interest ↓GMABGenmab A/S4.4914 of 5 stars$21.82+1.5%$45.20+107.1%-31.7%$14.44B$19.84B20.872,204SMMTSummit Therapeutics3.2229 of 5 stars$18.63+0.9%$34.75+86.5%+768.1%$13.74B$700,000.00-65.93105News CoveragePositive NewsSRPTSarepta Therapeutics4.9354 of 5 stars$126.99-4.8%$175.77+38.4%+51.5%$12.13B$1.24B101.421,314Analyst ForecastAnalyst RevisionRDYDr. Reddy's Laboratories1.4689 of 5 stars$14.31+1.2%$17.00+18.8%+2.8%$11.94B$299.87B22.5927,048PCVXVaxcyte2.2736 of 5 stars$92.17-2.3%$147.50+60.0%+70.2%$11.49BN/A-20.51160Positive NewsCTLTCatalent3.3547 of 5 stars$61.30+0.3%$63.40+3.4%+53.1%$11.13B$4.38B-27.0416,900Analyst UpgradeShort Interest ↑Positive NewsQGENQiagen3.9209 of 5 stars$43.74+0.7%$50.88+16.3%+2.2%$9.98B$1.97B111.365,967Analyst RevisionROIVRoivant Sciences3.6213 of 5 stars$12.57-1.1%$17.93+42.6%+26.7%$9.15B$129.13M2.23860Positive News Related Companies and Tools Related Companies MRNA Alternatives VTRS Alternatives GMAB Alternatives SMMT Alternatives SRPT Alternatives RDY Alternatives PCVX Alternatives CTLT Alternatives QGEN Alternatives ROIV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APLS) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
